On 5/16/2008 the FDA issued an alert for users of the immunosuppresants Mycophenolate Mofetil (marketed as CellCept) and Mycophenolic Acid (marketed as Myfortic). These drugs are commonly prescribed after organ transplants to prevent organ rejection, and have also been prescribed for immunemediated conditions such as systemic lupus erythematosus (SLE) and erythema multiforme.
Children Born With Birth Defects
These medications have led to reports of infants born with serious birth defects, including microtia (deformity of the outer ear) and cleft lip and palate. ...
continue reading...